| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| 25mg | |||
| Other Sizes |
| Targets |
SMAP-2 targets protein phosphatase 2A (PP2A), a serine/threonine phosphatase that functions as a tumor suppressor. By binding to the PP2A Aalpha scaffold subunit, SMAP-2 stabilizes PP2A activity, leading to dephosphorylation of oncogenic substrates and inhibition of tumor growth, particularly in KRAS-mutant lung cancers.
|
|---|---|
| ln Vitro |
Pancreatic ductal adenocarcinoma (PDA) cell lines exhibit dose-dependent reductions in cell viability due to SMAP-2 [2].
In vitro, SMAP-2 activates PP2A and inhibits the growth of KRAS-mutant lung cancer cells. The compound has demonstrated anti-cancer activity through PP2A-mediated dephosphorylation of key oncogenic signaling proteins. Specific IC₅0 values for cell growth inhibition are available in the primary literature. |
| ln Vivo |
In pre-AAA apolipoprotein E-deficient (ApoE-/-) mice, SMAP-2 dramatically lowers the incidence of abdominal aortic aneurysm (AAA) and aortic dilatation [2]. In a mouse model of pancreatic cancer, SMAP-2 (15 mg/kg; ig; daily; 6 days per week; for about 14 days) exhibits anti-tumor action [2].
In vivo, SMAP-2 dramatically lowers the incidence of abdominal aortic aneurysm (AAA) and aortic dilatation in pre-AAA apolipoprotein E-deficient (ApoE-/-) mice. The compound also exhibits anti-tumor activity in preclinical cancer models through PP2A activation. |
| Enzyme Assay |
For in vitro enzyme/receptor binding assays, SMAP-2 is evaluated using recombinant PP2A holoenzyme in phosphatase activity assays. The compound is incubated with PP2A and a phosphopeptide substrate, and activation is measured by increased phosphate release. Binding to the PP2A Aalpha scaffold subunit is confirmed using biophysical methods such as surface plasmon resonance or isothermal titration calorimetry.
|
| Cell Assay |
For in vitro cellular assays, SMAP-2 is dissolved in DMSO and applied to cancer cell lines, particularly those with KRAS mutations. PP2A activity, substrate phosphorylation (e.g., p-AKT, p-MYC), cell proliferation, and apoptosis are assessed using Western blotting, MTT assays, or flow cytometry.
|
| Animal Protocol |
Animal/Disease Models: NSG mice with PANC89 cell xenografts [2]
Doses: 15 mg/kg Route of Administration: Daily po (oral gavage), 6 days per week for approximately 14 days Experimental Results: Reduction in tumor growth and tumor weight . In vivo animal studies with SMAP-2 typically involve oral administration in mouse models of cancer or cardiovascular disease. For cancer studies, xenograft models are used to assess tumor growth inhibition. For AAA studies, ApoE-/- mice are treated to evaluate aneurysm prevention. |
| ADME/Pharmacokinetics |
Pharmacokinetic data for SMAP-2 indicate that the compound is orally bioavailable. It has a molecular weight of 532.57 and molecular formula C2₇H2₇F3N2O4S. The compound should be stored as a powder at -20degC for up to 3 years.
|
| Toxicity/Toxicokinetics |
Toxicology data for SMAP-2 are limited. As a PP2A activator, the compound modulates broad cellular signaling pathways. Preclinical studies have shown acceptable tolerability in animal models. Not approved for human use.
|
| References |
|
| Additional Infomation |
SMAP-2 (CAS#: 1809068-70-9) has the molecular formula C2₇H2₇F3N2O4S and molecular weight 532.57. The compound is an orally bioactive protein phosphatase 2A activator with anti-cancer and cardiovascular protective activities. It is supplied as a research reagent only.
|
| Molecular Formula |
C27H27F3N2O4S
|
|---|---|
| Molecular Weight |
532.574496507645
|
| Exact Mass |
532.164
|
| CAS # |
1809068-70-9
|
| PubChem CID |
91885560
|
| Appearance |
White to off-white solid powder
|
| LogP |
6.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
37
|
| Complexity |
835
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
S(C1C=CC(=CC=1)OC(F)(F)F)(N[C@H]1CCC[C@H]([C@@H]1O)N1C2C=CC=CC=2CCC2C=CC=CC1=2)(=O)=O
|
| InChi Key |
SDVKTCLBCCAFIS-HDYLNDSGSA-N
|
| InChi Code |
InChI=1S/C27H27F3N2O4S/c28-27(29,30)36-20-14-16-21(17-15-20)37(34,35)31-22-8-5-11-25(26(22)33)32-23-9-3-1-6-18(23)12-13-19-7-2-4-10-24(19)32/h1-4,6-7,9-10,14-17,22,25-26,31,33H,5,8,11-13H2/t22-,25+,26+/m0/s1
|
| Chemical Name |
N-[(1S,2S,3R)-3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-2-hydroxycyclohexyl]-4-(trifluoromethoxy)benzenesulfonamide
|
| Synonyms |
DT-1154SMAP-2 DT1154 SMAP2DT 1154
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~300 mg/mL (~563.31 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 7.5 mg/mL (14.08 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 75.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 7.5 mg/mL (14.08 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 75.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8777 mL | 9.3884 mL | 18.7769 mL | |
| 5 mM | 0.3755 mL | 1.8777 mL | 3.7554 mL | |
| 10 mM | 0.1878 mL | 0.9388 mL | 1.8777 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
